72.68 USD
+0.18
0.25%
At close Dec 24, 4:00 PM EST
After hours
72.68
+0.00
0.00%
1 day
0.25%
5 days
0.92%
1 month
-8.84%
3 months
-10.50%
6 months
0.28%
Year to date
0.30%
1 year
2.21%
5 years
38.20%
10 years
170.29%
 

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 7,063

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

133% more call options, than puts

Call options by funds: $82.9M | Put options by funds: $35.6M

32% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 73

8% more capital invested

Capital invested by funds: $17.1B [Q2] → $18.4B (+$1.33B) [Q3]

3% more funds holding

Funds holding: 687 [Q2] → 710 (+23) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 260 | Existing positions reduced: 264

1.86% less ownership

Funds ownership: 98.72% [Q2] → 96.86% (-1.86%) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$82
13%
upside
Avg. target
$89
22%
upside
High target
$95
31%
upside

10 analyst ratings

positive
50%
neutral
50%
negative
0%
Needham
Mike Matson
49% 1-year accuracy
57 / 117 met price target
24%upside
$90
Buy
Reiterated
19 Dec 2024
Jefferies
Tycho Peterson
50% 1-year accuracy
6 / 12 met price target
17%upside
$85
Hold
Initiated
10 Dec 2024
Raymond James
Andrew Cooper
17% 1-year accuracy
2 / 12 met price target
31%upside
$95
Outperform
Maintained
5 Nov 2024
Mizuho
Anthony Petrone
39% 1-year accuracy
15 / 38 met price target
20%upside
$87
Outperform
Maintained
5 Nov 2024
UBS
Elizabeth Garcia
50% 1-year accuracy
1 / 2 met price target
24%upside
$90
Neutral
Maintained
5 Nov 2024

Financial journalist opinion

Based on 14 articles about HOLX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Positive
Zacks Investment Research
1 day ago
Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?
Via an agreement with the CDC, Hologic is set to develop ASRs for launching the H5N1 bird flu test.
Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?
Negative
Zacks Investment Research
5 days ago
Here's Why Hologic (HOLX) Fell More Than Broader Market
Hologic (HOLX) closed the most recent trading day at $70.76, moving -0.99% from the previous trading session.
Here's Why Hologic (HOLX) Fell More Than Broader Market
Neutral
Business Wire
1 week ago
Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #H5N1--Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC.
Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC
Positive
Zacks Investment Research
1 week ago
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Positive
Zacks Investment Research
2 weeks ago
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
Neutral
Business Wire
2 weeks ago
Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #USPSTF--Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines.
Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines
Neutral
Business Wire
2 weeks ago
Martin Madaus Elected to Hologic Board of Directors
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #boardofdirectors--Martin Madaus Elected to Hologic Board of Directors.
Martin Madaus Elected to Hologic Board of Directors
Neutral
Business Wire
2 weeks ago
New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--New Data To Be Presented at SABCS 2024 Investigates the Potential Role of Breast Cancer IndexTest.
New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence
Positive
Zacks Investment Research
3 weeks ago
HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0
Hologic upholds its focus on equity with new research findings on its Breast Imaging AI solution.
HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0
Charts implemented using Lightweight Charts™